Scientists are a step closer to finding the first effective treatments for the deadly Ebola hemorrhagic fever after two potential drugs showed encouraging survival results in a clinical trial in Congo.
Two experimental drugs — Regeneron's REGN-EB3 and a monoclonal antibody called mAb114 — were both developed using antibodies harvested from survivors of Ebola infection.
They showed "clearly better" results in patients in a trial of four potential treatments being conducted during the world's second-largest Ebola outbreak in history, now entering its second year in the Democratic Republic of Congo.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.